IL7 and neoplasm: In a phase I/II clinical trial (NCT00923351) (88), recombinant human IL-7 was administered to pediatric sarcoma patients on days 0, 14 ± 7 d, 28 ± 7 d, and 42 ± 7 d after receiving autologous tumor lysate-pulsed DCs vaccination.